Hepatitis B surface antigen positivity is associated with progression of disease within 24 months in follicular lymphoma

• Published in: Journal of cancer research and clinical oncology 2022-05, Vol.148 (5), p.1211-1222
• Main Authors: Cheng, Chieh-Lung, Fang, Wei-Quan, Lin, Yu-Jen, Yuan, Chang-Tsu, Ko, Bor-Sheng, Tang, Jih-Luh, Tien, Hwei-Fang
• Format: Article
• Language: English
• Subjects: Antigens; Cancer Research; Chronic infection; Hematology; Hepatitis B; Hepatitis B - complications; Hepatitis B - drug therapy; Hepatitis B surface antigen; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Infections; Internal Medicine; Lymphoma; Lymphoma, Follicular - drug therapy; Medical prognosis; Medicine; Medicine & Public Health; Multivariate analysis; Oncology; Original Article – Clinical Oncology; Patients; Prognosis; Remission; Retrospective Studies; Rituximab; Rituximab - therapeutic use; Splenomegaly; Survival
• ISSN: 0171-5216; 1432-1335
• DOI: 10.1007/s00432-021-03719-y

Purpose Studies have reported a positive association between hepatitis B surface antigen (HBsAg)-positive hepatitis B virus (HBV) infection and follicular lymphoma (FL). Nevertheless, clinical information concerning chronic HBV infection in FL is sparse. Methods This retrospective cohort study investigated the prognostic impact of HBsAg in immunocompetent patients with FL treated with frontline rituximab-containing chemoimmunotherapy in an HBV-endemic area between 2006 and 2016. Results Among the 149 analyzed patients, 32 (21.5%) were HBsAg-positive. HBsAg positivity was positively associated with symptomatic splenomegaly, significant serous effusions, and peritreatment hepatic dysfunction. HBsAg-positive patients had a trend of lower complete remission rate (59.4% vs. 76.9%, P  = 0.07), significantly poorer overall survival (hazard ratio for death, 2.68; 95% confidence interval, 1.21–5.92), and shorter progression-free survival than had HBsAg-negative patients. Multivariate analysis revealed that HBsAg is an independent adverse prognostic factor for overall survival. Intriguingly, HBsAg-positive patients had a higher incidence of progression of disease within 24 months (POD24) than had HBsAg-negative patients (cumulative incidence rate, 25.8% vs. 12.4%, P  = 0.045). Conclusion This study revealed that patients with FL and chronic HBV infection represent a distinct subgroup with a markedly poor prognosis. HBsAg was positively associated with POD24 and might serve as a new prognostic predictor of the survival of FL patients in endemic regions for HBV infection.